arXane › Quantitative Biology › Quantitative Biology
Wednesday, 4 November 2026: 2 new papers, 4 cross-lists and 2 replacements in Biomolecules (q-bio.BM), in arXiv's order, with full abstracts. The same papers as arXiv's own listing, set as a newspaper; every title links to arXiv.
Protein structure predictors reliably identify native conformations, but do not describe the continuum connecting unfolded ensembles to folded states. Here we present FoldScape, a sequence-conditioned deep learning framework that generates C$\alpha$ conformational ensembles at a specified folding fraction $Q$. FoldScape reconstructs three-dimensional chains through hierarchical, sliding-window regressions of one-dimensional inter-residue distances, followed by chain assembly and sampling with a rectified-flow decoder. It is trained on multi-scale coarse-grained folding trajectories and all-atom mechanical-unfolding trajectories. Across 20 human proteins (36-857 residues), at matched sample size, FoldScape covers about an order of magnitude more of the folding coordinate than seed-varied AlphaFold 3 ensembles, robustly across proteins, order parameters and binning choices. AlphaFold 3 better anchors the immediate native vicinity, which FoldScape does not reach, making the approaches complementary. FoldScape reconstruction accuracy remains approximately constant along $Q$, from collapsed coil to near-native globule, rather than deteriorating away from the native state. A stride-one crop-and-superpose scheme extends inference to chains several times longer than a single chain-level forward pass. We also show that training trajectories resolve mechanical unfolding at residue resolution, that elongation-conditioned ensembles exhibit reproducible continuous observables across pulling velocities, and that partially unfolded chains form geometrically coherent segments. FoldScape thus combines broad coverage of folding stages with stable reconstruction accuracy, without per-protein simulation.
Generative models of protein conformational ensembles inherit much of their design from structure prediction for folded proteins. Ordered and disordered proteins, however, occupy distinct structural regimes, and we investigate how design choices hold up across them. Using a minimal C$\alpha$ flow-matching model, we ablate choices of architecture, sequence conditioning, rigid-body alignment and training source, and evaluate each variant against experimental SAXS and NMR chemical-shift data partitioned into ordered, disordered, multi-domain and transitional proteins. Mixture-of-experts routing, a static pair representation and a disorder probe have no detectable effect, a smaller protein language model performs worse on ordered proteins but not on disordered ones, and alignment in the loss degrades agreement with SAXS. Replacing coarse-grained simulations of disordered proteins with fragment-assembled ensembles improves agreement with chemical shifts at a cost to SAXS, while an equal mixture of the two keeps most of the gain at a smaller cost. This points to the training data, rather than the architecture, as the main constraint.
Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente F\'armaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: F\'armaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. F\'armaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.
Protein-protein interactions underpin nearly all biological processes. Yet, designing proteins with desired interactions remains challenging due to the structural complexity governing molecular recognition. This study views protein design as a search optimization problem over a combinatorial sequence space under expensive structural evaluation. Toward this goal, we introduce a novel tree-based search framework, ProteoCraft, that employs approximate structural gradients from diffusion-based structure predictors as effective proposal policies to specify where the search should explore. Complete no-gradient inference of folding models separately assigns values to the resulting sequences, determining what is good. ProteoCraft allocates this verification budget through a coarse-to-fine paradigm: multi-site edits first explore distinct sequence basins, then verified promising states undergo strict single-site refinement. Across fourteen de novo binder-design settings spanning eight target proteins, five immune-relevant TCR-facing targets, and four localized CDR redesign tasks, ProteoCraft improves design quality and high-confidence yield. These improvements persist under independent AF2-IG and Rosetta-based interface evaluation. Prospective experimental validation further yielded an 82.9% binding hit rate for PD-L1 miniproteins, with a best measured KD of 0.879 nM, and confirmed binding of designed IFNAR2 VHH. Our code is available at https://github.com/smiles724/ProteoCraft_v1.
We address the problem of learning generative priors over high-dimensional latent variables from indirect, noisy observations, with a focus on continuous heterogeneity in cryo-electron microscopy (cryo-EM). In this setting, 3D atomic structures $x \in \mathbb{R}^{3N_a}$ are never directly observed and must be inferred from 2D projection images $y$ generated by a complex, non-linear forward operator. We propose Empirical Bayes Flow Matching (EB-FM), a method that learns a flow matching prior $p_\theta(x)$ directly from observations using a Monte Carlo stochastic approximation Expectation-Maximization framework. EB-FM alternates between an E-step that performs approximate posterior sampling from $p_\theta(x \mid y)$ via guided flow-based generation while maintaining persistent latent estimates through stochastic approximation, and an M-step that updates the flow model using these stabilized latent variables as training targets. This approach eliminates the need for pretraining on clean data and naturally accommodates non-linear forward models. We validate our method on controlled inverse problems using two-moons and MNIST data, and demonstrate its effectiveness on simulated cryo-EM data with known poses, showing that EB-FM can recover continuous distributions of protein conformations directly in atomic-coordinate space.
Antibody affinity maturation is a natural optimization process in which B cells acquire mutations through somatic hypermutation (SHM), undergo selection for improved antigen binding, and iteratively evolve toward higher affinity. Computationally modeling this process requires capturing both biologically plausible mutations and antigen-specific selection. However, existing mutation models do not directly optimize binding, while affinity optimization often neglects realistic mutation trajectories. We introduce iGC (in silico Germinal Centers), a two-stage reinforcement learning (RL) framework for antigen-specific antibody optimization. Stage 1 learns an SHM mutation prior from parent-child pairs in B-cell lineage trees and adapts it to a target affinity-maturation dataset. Stage 2 initializes an RL policy from this prior and optimizes antigen binding with Kullback-Leibler (KL) regularization toward the frozen prior. To prevent reward exploitation, including repetitive high-reward substitutions and structurally tolerated framework mutations, we introduce a Reward-Tax Meta-Gradient objective. RewardNet smooths the affinity landscape, while TaxNet penalizes reward overexploitation, jointly defining a learned meta-reward for policy optimization. We evaluate iGC on mutation prediction, SHM consistency, affinity optimization, and mutation diversity. The mutation prior more than doubles the strongest baseline in mutation-site prediction. Following RL optimization, iGC maintains SHM sequence structure. It also achieves a strong exploration-exploitation balance, yielding competitive reward-diversity products across candidate-selection cutoffs. These results demonstrate that iGC integrates biologically plausible mutation generation with antigen-specific affinity selection, providing an in silico framework for iterative antibody affinity maturation.